{"pmid":32424845,"title":"Artemisia annua: trials are needed for COVID-19.","text":["Artemisia annua: trials are needed for COVID-19.","In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS-CoV-2 and disease called COVID-19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS-CoV-2. COVID-19 is great challenge for scientist across the globe. Bioactive compound present in Artemisia annua against, hepatitis B virus, bovine viral diarrhea virus and Epstein-Barr virus. Artemisia annua have shown significant activity against SARS coronavirus that occur in 2002. This agent is cheap and easily available and will be of great value if they have efficacy against SARS-COV-2. Scientific attention is needed towards these agent to address for the treatment of COVID-19. This article is protected by copyright. All rights reserved.","Phytother Res","Haq, Faiz Ul","Roman, Muhammad","Ahmad, Kashif","Rahman, Saeed Ur","Shah, Syed Murtaza Ali","Suleman, Naveed","Ullah, Sami","Ahmad, Iftekhar","Ullah, Wajahat","32424845"],"abstract":["In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS-CoV-2 and disease called COVID-19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS-CoV-2. COVID-19 is great challenge for scientist across the globe. Bioactive compound present in Artemisia annua against, hepatitis B virus, bovine viral diarrhea virus and Epstein-Barr virus. Artemisia annua have shown significant activity against SARS coronavirus that occur in 2002. This agent is cheap and easily available and will be of great value if they have efficacy against SARS-COV-2. Scientific attention is needed towards these agent to address for the treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"Phytother Res","authors":["Haq, Faiz Ul","Roman, Muhammad","Ahmad, Kashif","Rahman, Saeed Ur","Shah, Syed Murtaza Ali","Suleman, Naveed","Ullah, Sami","Ahmad, Iftekhar","Ullah, Wajahat"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424845","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/ptr.6733","keywords":["artemisia annua","coronavirus: antiviral agents: covid-19","sars-cov-2","bioactive compound"],"locations":["Wuhan","China","Artemisia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667352728697831424,"score":9.490897,"similar":[{"pmid":32379639,"pmcid":"PMC7152923","title":"Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines.","text":["Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines.","This review aimed to summarize and analyze the pattern identification (PI), herbal formulae, and composition of herbs provided by recent guidelines for the treatment of pediatric COVID-19. Seven data sources were reviewed until March 25, 2020. We analyzed the herbal formulae included in the guidelines and performed a network analysis to identify the frequency of herbs recommended in the herbal formulae. All 3 guidelines were provincial guidelines from China. Our results showed that there were 4 stages, 12 PIs, and 13 herbal formulae recommended by the provincial guidelines. These herbal formulae included a total of 56 herbs. Based on our network analysis, Scutellariae Radix was paired with Artemisiae Annuae Herba in one cluster. In another cluster, Armeniacae Semen was paired with Coicis Semen and Ephedrae Herba was paired with Gypsum Fibrosum. This review serves as a reference for the use of traditional medicine in the treatment of pediatric COVID-19.","Complement Ther Clin Pract","Ang, Lin","Lee, Hye Won","Kim, Anna","Lee, Ju Ah","Zhang, Junhua","Lee, Myeong Soo","32379639"],"abstract":["This review aimed to summarize and analyze the pattern identification (PI), herbal formulae, and composition of herbs provided by recent guidelines for the treatment of pediatric COVID-19. Seven data sources were reviewed until March 25, 2020. We analyzed the herbal formulae included in the guidelines and performed a network analysis to identify the frequency of herbs recommended in the herbal formulae. All 3 guidelines were provincial guidelines from China. Our results showed that there were 4 stages, 12 PIs, and 13 herbal formulae recommended by the provincial guidelines. These herbal formulae included a total of 56 herbs. Based on our network analysis, Scutellariae Radix was paired with Artemisiae Annuae Herba in one cluster. In another cluster, Armeniacae Semen was paired with Coicis Semen and Ephedrae Herba was paired with Gypsum Fibrosum. This review serves as a reference for the use of traditional medicine in the treatment of pediatric COVID-19."],"journal":"Complement Ther Clin Pract","authors":["Ang, Lin","Lee, Hye Won","Kim, Anna","Lee, Ju Ah","Zhang, Junhua","Lee, Myeong Soo"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379639","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ctcp.2020.101174","keywords":["covid-19","children","herbal medicine","pediatric","traditional medicine"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666262687634423808,"score":150.20468},{"pmid":32405226,"pmcid":"PMC7217791","title":"Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","text":["Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties.","Pharmacol Res","Cheong, Dorothy H J","Daniel Tan, W S","Fred Wong, W S","Tran, Thai","32405226"],"abstract":["Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties."],"journal":"Pharmacol Res","authors":["Cheong, Dorothy H J","Daniel Tan, W S","Fred Wong, W S","Tran, Thai"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405226","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104901","keywords":["2dg, 2-deoxy-d-glucose","3-nt, 3-nitrotyrosine","4ebp1, eukaryotic translation initiation factor 4e-binding protein 1","8-ohdg, 8-hydroxy-2'-deoxyguanosine","8-iso, 8-isoprostane","abcg2, atp-binding cassette subfamily member 2","ace2, angiotensin-converting enzyme 2","aec, alveolar epithelial cells","ahr, airway hyperresponsiveness","aif, apoptosis-inducing factor","ali, acute lung injury","ap-1, activator protein 1","artd, artemisinin-daumone hybrid 15","asc, apoptosis-associated speck-like protein containing card","atf3, activating transcription factor 3","atp, adenosine triphosphate","arteether (pubchem cid: 3000469)","artemether (pubchem cid: 68911)","artemisitene (pubchem cid: 11000442)","artesunate (pubchem cid:156252)","axin2, axis inhibition protein 2","balf, bronchoalveolar lavage fluid","bdha, biotinylated dihydroartesunate","cddp, cisplatin","cdk, cyclin-dependent kinase","copd, chronic obstructive pulmonary disease","covid-19","cox-2, cyclooxygenase-2","cse, cigarette smoke extract","ctx, cyclophosphamide","chemical compounds studied in this article artemisinin (pubchem cid: 68827)","dha, dihydroartemisinin","dha-nlc, dihydroartemisinin-nanostructured lipid carriers","dlaedried, leaf artemisia extract","dna, deoxyribonucleic acid","dihydroartemisinin (pubchem cid: 139073990)","e2f1, e2f transcription factor 1","egfr, epidermal growth factor receptor","emt, epithelial-mesenchymal transition","er, endoplasmic reticulum","foxo1, forkhead box o1","glut, glucose transporter","gpx, glutathione peroxidase","gsh, glutathione","gsk3beta, glycogen synthase kinase 3 beta","h2ax, h2a histone family member x","hcmv, human cytomegalovirus","hdac2, histone deacetylase 2","helf, human embryonic lung fibroblasts","hif-1alpha, hypoxia-inducible factor 1-alpha","hnf4a, hepatocyte nuclear factor 4 alpha","ho-1, heme oxygenase-1","icam-1, intercellular adhesion molecule 1","il, interleukin","inf, interferon","ip-10, ifngamma-induced protein 10","ikappabalpha, inhibitor of nf-kappab alpha","jnk, c-jun n-terminal kinase","kc, keratinocyte chemoattractant","kdr/flk-1, kinase insert domain receptor /fetal liver kinase-1","keap1, kelch-like ech-associated protein 1","ladpi, liposomal artesunate dry powder inhalers","ld50, lethal dose","llc, lewis lung carcinoma","lmvd, lymphatic microvessel density","lps, lipopolysaccharide","lymp, lymphocyte","mapk, mitogen-activated protein kinases","mcp-1, monocyte chemoattractant protein-1","mda, malondialdehyde","mip-2, macrophage inflammatory protein 2","mmp, matrix metalloproteinase","mpo, myeloperoxidase","mac, macrophage","mcl-1, myeloid cell leukemia-1","nf-kappab, nuclear factor-kappa b","nkd2, naked cuticle homolog 2","nlrp3, nlr family pyrin domain containing 3","no, nitric oxide","nox, nadph oxidase","npc, nasopharyngeal carcinoma","nqo1, nad(p)h quinone dehydrogenase 1","nsclc, non-small cell lung cancer","nrf2, nuclear factor erythroid 2-related factor 2","ova, ovalbumin","pcna, proliferating cell nuclear antigen","peg, polyethylene glycol","pge2, prostaglandin e2","pi3k, phosphoinositide 3-kinase","ra, fls rheumatoid arthritis fibroblast-like synoviocytes","rankl, receptor activator of nuclear factor kappa-b ligand","rir, renal ischemia reperfusion","rnai, rna interference","ros, reactive oxygen species","rb, retinoblastoma","respiratory diseases","sclc, small cell lung cancer","sle, systemic lupus erythematosus","sod, superoxide dismutase","stat, signal transducers and activators of transcription","smac, second mitochondrial activator of caspases","tgf, tumour growth factor","timp, tissue inhibitor of metalloproteinases","tlr4, toll-like receptor 4","tnf, tumour necrosis factor","tslp, thymic stromal lymphopoietin","th17, t helper 17","treg, regulatory t","vcam-1, vascular cell adhesion molecule 1","vdac2, voltage-dependent anion channel 2","vegf, vascular endothelial growth factor","xiap, x-linked inhibitor of apoptosis protein","ykl-40, chitinase-like glycoprotein","ym2, chitinase 3-like protein 4","[ca2+]i, intracellular calcium ion","artemisinin","cell proliferation","eos, eosinophil","hsp47, heat shock protein 47","inos, inducible nitric oxide synthase","inflammation","lung","mtor, mammalian target of rapamycin","neu, neutrophil","shrna, short hairpin rna","sm-alpha, actin smooth muscle-alpha actin","u-pa, urokinase-type plasminogen activator"],"e_drugs":["artemisinine","Reactive Oxygen Species","Peroxides","Artemisinins"],"topics":["Treatment"],"weight":1,"_version_":1666802845647634432,"score":145.91676},{"pmid":32475812,"title":"Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","text":["Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.","Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making it effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties.","Pharmacol Res","Cheong, Dorothy H J","Tan, Daniel W S","Wong, Fred W S","Tran, Thai","32475812"],"abstract":["Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making it effective against diseases. Moreover, it has displayed a relatively safe toxicity profile. The use of artemisinins against different respiratory diseases has been investigated in lung cancer models and inflammatory-driven respiratory disorders. These studies revealed the ability of artemisinins in attenuating proliferation, inflammation, invasion, and metastasis, and in inducing apoptosis. Artemisinins can regulate the expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-kappaB), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), promote cell cycle arrest, drive reactive oxygen species (ROS) production and induce Bak or Bax-dependent or independent apoptosis. In this review, we aim to provide a comprehensive update of the current knowledge of the effects of artemisinins in relation to respiratory diseases to identify gaps that need to be filled in the course of repurposing artemisinins for the treatment of respiratory diseases. In addition, we postulate whether artemisinins can also be repurposed for the treatment of COVID-19 given its anti-viral and anti-inflammatory properties."],"journal":"Pharmacol Res","authors":["Cheong, Dorothy H J","Tan, Daniel W S","Wong, Fred W S","Tran, Thai"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475812","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.phrs.2020.104901","keywords":["arteether (pubchem cid: 3000469)","artemether (pubchem cid: 68911)","artemisinin","artemisitene (pubchem cid: 11000442)","artesunate (pubchem cid:156252)","covid-19","cell proliferation","chemical compounds studied in this article artemisinin (pubchem cid: 68827)","dihydroartemisinin (pubchem cid: 139073990)","inflammation","lung","respiratory diseases"],"topics":["Treatment"],"weight":1,"_version_":1668437835209768960,"score":145.91676},{"pmid":32340120,"title":"Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19.","text":["Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19.","The whole world is currently facing an unseen enemy, called coronavirus disease 2019 (COVID-19), which is causing a global pandemic. This disease is caused by a novel single-stranded enveloped RNA virus, known as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Although huge efforts are being made to produce effective therapies to combat this disease, it continues to be one of the greatest challenges in medicine. There is no doubt that herpesviruses are one of the most important viruses that infect humans and animals, and infections induced by these pathogens have developed into a great threat to public health. According to the currently available evidence, the correlation between herpesviruses and coronaviruses is limited to the induced complications following the infections. For instance, the inflammation that is induced at the sites of infection could tie these viruses to each other in a relationship. Another example, bovine herpesvirus 1, which is an important pathogen of cattle, can cause a severe respiratory infection; the same way in which SARS-CoV-2 affects humans. Considering the current circumstances related to the COVID-19 crisis, this editorial paper, which belongs to the Special Issue \"Recent Advances in Herpesviruses Research: What's in the Pipeline?\" aims to draw attention to some natural anti-herpesvirus alkaloid compounds, which have recently been proven to have excellent inhibitory efficacy against SARS-CoV-2 replication. Thus, this special focus is an attempt to hunt down various treatment options to combat COVID-19 based on repurposing drugs that are known to have multiple antiviral properties, including against herpesvirus.","Viruses","Hassan, Sherif T S","32340120"],"abstract":["The whole world is currently facing an unseen enemy, called coronavirus disease 2019 (COVID-19), which is causing a global pandemic. This disease is caused by a novel single-stranded enveloped RNA virus, known as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Although huge efforts are being made to produce effective therapies to combat this disease, it continues to be one of the greatest challenges in medicine. There is no doubt that herpesviruses are one of the most important viruses that infect humans and animals, and infections induced by these pathogens have developed into a great threat to public health. According to the currently available evidence, the correlation between herpesviruses and coronaviruses is limited to the induced complications following the infections. For instance, the inflammation that is induced at the sites of infection could tie these viruses to each other in a relationship. Another example, bovine herpesvirus 1, which is an important pathogen of cattle, can cause a severe respiratory infection; the same way in which SARS-CoV-2 affects humans. Considering the current circumstances related to the COVID-19 crisis, this editorial paper, which belongs to the Special Issue \"Recent Advances in Herpesviruses Research: What's in the Pipeline?\" aims to draw attention to some natural anti-herpesvirus alkaloid compounds, which have recently been proven to have excellent inhibitory efficacy against SARS-CoV-2 replication. Thus, this special focus is an attempt to hunt down various treatment options to combat COVID-19 based on repurposing drugs that are known to have multiple antiviral properties, including against herpesvirus."],"journal":"Viruses","authors":["Hassan, Sherif T S"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340120","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3390/v12040476","keywords":["covid-19","sars-cov-2","alkaloids","anti-herpesvirus drugs","herpesviruses"],"topics":["Treatment"],"weight":1,"_version_":1666138495788253184,"score":136.7088},{"pmid":32245083,"pmcid":"PMC7157541","title":"SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.","text":["SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.","In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes.","Pathogens","Rabi, Firas A","Al Zoubi, Mazhar S","Kasasbeh, Ghena A","Salameh, Dunia M","Al-Nasser, Amjad D","32245083"],"abstract":["In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes."],"journal":"Pathogens","authors":["Rabi, Firas A","Al Zoubi, Mazhar S","Kasasbeh, Ghena A","Salameh, Dunia M","Al-Nasser, Amjad D"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245083","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.3390/pathogens9030231","keywords":["covid-19","coronavirus","sars","sars-cov-2","wuhan","pandemic"],"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment","Diagnosis"],"weight":1,"_version_":1666138492019671040,"score":132.25375}]}